List of Excipients in Branded Drug stribild

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
State of Florida DOH Central Pharmacy	STRIBILD	elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate	53808-0887	ALUMINUM OXIDE	2027-04-26
State of Florida DOH Central Pharmacy	STRIBILD	elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate	53808-0887	CELLULOSE, MICROCRYSTALLINE	2027-04-26
State of Florida DOH Central Pharmacy	STRIBILD	elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate	53808-0887	COLLOIDAL SILICON DIOXIDE	2027-04-26
State of Florida DOH Central Pharmacy	STRIBILD	elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate	53808-0887	CROSCARMELLOSE SODIUM	2027-04-26
State of Florida DOH Central Pharmacy	STRIBILD	elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate	53808-0887	FD&C BLUE NO. 2	2027-04-26

Stribild Excipient Strategy and Commercial Opportunities

Last updated: August 13, 2026

Stribild is a fixed-dose HIV-1 treatment containing elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate. Its commercial value has declined as Gilead shifted patients toward TAF-based Genvoya and bictegravir-based Biktarvy. The principal excipient opportunity is therefore not a new branded Stribild launch. It is the development of generic, differentiated, or contract-manufactured products using a robust high-load tablet platform, improved stability controls, and lower-cost supply chains.

The formulation relies on conventional solid-dose excipients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, colloidal silicon dioxide, sodium lauryl sulfate, and a film-coating system containing polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, and iron oxide [1, 2]. The formulation is technically reproducible, but the active pharmaceutical ingredient burden, low-dose/high-potency combination, cobicistat interaction profile, and need for bioequivalence create meaningful development barriers.

What is Stribild and how does its formulation work?

Stribild is a once-daily, four-drug tablet approved by the FDA in August 2012 for treatment of HIV-1 infection in adults without prior antiretroviral treatment and, under later labeling, in certain virologically suppressed patients [1].

What active ingredients are in Stribild?

Component	Function in therapy	Formulation relevance
Elvitegravir	Integrase strand transfer inhibitor	Low-dose, high-potency drug requiring controlled content uniformity
Cobicistat	Pharmacokinetic enhancer	Inhibits CYP3A and increases elvitegravir exposure
Emtricitabine	Nucleoside reverse transcriptase inhibitor	Water-soluble antiviral with established oral solid-dose manufacturing history
Tenofovir disoproxil fumarate	Nucleotide reverse transcriptase inhibitor	Moisture-sensitive prodrug with known renal and bone safety considerations

The tablet contains 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil [1].

What excipients are used in Stribild tablets?

The Stribild tablet core contains:

• Croscarmellose sodium
• Hydroxypropyl cellulose
• Lactose monohydrate
• Magnesium stearate
• Microcrystalline cellulose
• Silicon dioxide
• Sodium lauryl sulfate

The film coating contains:

• Iron oxide yellow
• Polyethylene glycol
• Polyvinyl alcohol
• Talc
• Titanium dioxide

These excipients perform standard functions. Microcrystalline cellulose provides bulk and compactibility. Croscarmellose sodium supports rapid tablet breakup. Hydroxypropyl cellulose acts as a binder. Magnesium stearate reduces tooling friction. Silicon dioxide improves powder flow. Sodium lauryl sulfate supports wetting of poorly soluble components. The film coat protects the tablet surface, controls appearance, and improves swallowability [1, 2].

What excipient strategy is most suitable for a Stribild generic?

A generic Stribild strategy should prioritize formulation equivalence, process robustness, and supply security rather than aggressive excipient substitution. The reference product uses a conventional immediate-release tablet platform, which reduces the technical justification for a novel delivery system.

Which excipients are commercially important?

The highest-value excipient decisions concern:

1. Disintegrant performance. Croscarmellose sodium must provide rapid and reproducible tablet disintegration despite the high active load.
2. Lubrication control. Excess magnesium stearate can reduce tablet wettability and dissolution.
3. Moisture management. Tenofovir disoproxil fumarate requires control of humidity, water activity, and packaging exposure.
4. Blend uniformity. Elvitegravir and cobicistat are present at lower mass than the nucleoside components, creating segregation and content-uniformity risks.
5. Wetting enhancement. Sodium lauryl sulfate can improve dissolution but may affect tablet mechanical properties and gastrointestinal tolerability at excessive levels.
6. Film-coat reproducibility. Color and coating weight must remain consistent with the reference product and regulatory specifications.

A Q1/Q2 formulation using the same excipient classes and closely matched quantities generally offers the lowest regulatory risk. Substituting excipients may be commercially attractive when lactose intolerance, regional availability, or cost is a concern, but the applicant must demonstrate that the changes do not affect dissolution, stability, bioavailability, or impurity formation.

Can Stribild be reformulated without lactose?

Yes, a lactose-free generic is technically plausible. Lactose monohydrate can be replaced with mannitol, anhydrous dibasic calcium phosphate, silicified microcrystalline cellulose, or another qualified diluent. The substitution changes powder flow, compressibility, water activity, and tablet weight. A lactose-free product could target patients with lactose sensitivity and markets where lactose-free labeling has commercial value.

The opportunity is limited by the fact that lactose in an oral tablet is usually present at a low level and is not a major purchasing barrier for most patients. The strongest rationale for replacement is manufacturing or supply-chain performance, not broad clinical differentiation.

What formulation patents protect Stribild?

Stribild protection historically depended more heavily on patents covering the active ingredients, combinations, and methods of treatment than on commercially distinctive excipient technology.

Are Stribild excipients protected by formulation patents?

The listed excipients are well-established pharmaceutical materials. Their individual use in an immediate-release tablet is unlikely to create a durable standalone exclusivity position. Patent value would instead arise from a claim directed to:

• A specific ratio of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate
• A defined dissolution profile
• A stabilizing excipient combination
• A moisture-control system
• A particular granulation or compression process
• A specific solid-state form or impurity-control method
• A fixed-dose composition with a defined pharmacokinetic profile

A generic developer should separate three questions: whether the reference product has active Orange Book-listed patents, whether unlisted or expired formulation patents remain relevant, and whether process or solid-state patents create practical freedom-to-operate constraints.

What is the Orange Book status of Stribild?

Stribild was approved under NDA 203100. Its five-year new chemical entity exclusivity period began with FDA approval in 2012 and expired in 2017, subject to any pediatric extension. The product’s principal market protection is therefore historical rather than based on new chemical entity exclusivity [1, 3].

The FDA Orange Book remains the controlling source for current listed patents, expiry dates, pediatric extensions, and any approved generic applications [3]. A Paragraph IV filing would require a certification against each unexpired listed patent, while a Paragraph III filing could defer approval until patent expiry. A Section viii statement could be relevant for method-of-use patents if the applicant omits the protected indication from its labeling.

When did Stribild lose exclusivity?

Stribild lost core NCE exclusivity in 2017. Patent expiry dates depend on the specific patent family, terminal disclaimers, pediatric extensions, and any regulatory exclusivity attached to the application.

Protection category	Stribild position
FDA approval	August 27, 2012
NCE exclusivity	Generally expired in 2017
Pediatric exclusivity	Potential six-month extension if awarded for qualifying studies
Orphan exclusivity	Not the principal Stribild protection mechanism
Biosimilar exclusivity	Not applicable
Generic pathway	ANDA pathway, subject to patent certifications and bioequivalence
Combination-product patent risk	May remain relevant after NCE expiry

The commercial effect of exclusivity loss is moderated by the product’s declining clinical position. Physicians and payers increasingly favor TAF-based or bictegravir-based regimens, which can reduce the addressable market for a late generic Stribild even when regulatory entry is available.

What generic entry risks exist for Stribild?

The largest risks are technical and commercial rather than basic excipient availability.

What are the bioequivalence challenges?

A Stribild generic must establish bioequivalence for four active ingredients in a single fixed-dose tablet. The applicant must control:

• Assay and content uniformity for elvitegravir and cobicistat
• Dissolution for all four actives
• Food-effect performance
• Tablet hardness and friability
• Degradation products associated with tenofovir disoproxil fumarate
• Stability under accelerated and long-term conditions
• Batch-to-batch blend uniformity

The low-dose components create a particular risk. A formulation that achieves good average assay results can still fail content-uniformity requirements if segregation occurs during blending, transfer, or compression.

How does tenofovir disoproxil fumarate affect excipient selection?

Tenofovir disoproxil fumarate is vulnerable to degradation under unfavorable moisture and temperature conditions. The excipient system should minimize residual water and avoid processing conditions that accelerate hydrolysis. Packaging is part of the formulation strategy. High-barrier bottles, desiccants, or blister systems can protect product quality, although packaging changes may affect cost and patient adherence.

A manufacturer seeking a low-cost product may favor bottle packaging. A premium generic or emerging-market supplier may use high-barrier blister packaging to improve stability and reduce bottle-opening exposure. The best option depends on climate-zone requirements, distribution duration, and local packaging costs.

What commercial opportunities exist in Stribild excipients?

The commercial opportunity is strongest in enabling technologies and supply-chain services rather than proprietary excipient ownership.

Which excipient suppliers could benefit?

Potential suppliers include manufacturers of:

• Direct-compression microcrystalline cellulose
• High-performance croscarmellose sodium
• Low-moisture lactose
• Co-processed excipients
• Pharmaceutical-grade colloidal silicon dioxide
• Controlled-particle-size magnesium stearate
• Polyvinyl alcohol film-coating systems
• Moisture-barrier packaging materials

A supplier can create value by offering tighter particle-size distributions, lower moisture grades, improved flow, or validated performance in high-load antiretroviral tablets. The strongest commercial position comes from a formulation package that reduces development time and failed stability batches.

Can co-processed excipients improve Stribild manufacturing?

Co-processed microcrystalline cellulose systems containing a disintegrant or flow aid could reduce segregation and improve compaction. They may support direct compression and reduce wet-granulation steps. The trade-off is regulatory comparability. A co-processed excipient can simplify manufacturing but may require more extensive characterization than a conventional Q1/Q2 substitution.

The opportunity is most credible for manufacturers that need to produce the tablet in facilities with limited granulation capacity or that want to reduce processing time and solvent exposure.

Is there a market for pediatric or geriatric Stribild formulations?

A pediatric opportunity exists in principle, but Stribild’s four-drug combination, drug-interaction profile, and successor products limit the commercial case. Smaller tablets, dispersible tablets, oral granules, or age-appropriate dosage forms could improve administration. Any such product would require significant development work because changing the dosage form can alter dissolution, pharmacokinetics, and dosing flexibility.

A more practical opportunity is a patient-friendly generic tablet with improved swallowability, lower tablet weight, or packaging designed for adherence. These changes can support procurement contracts without creating a strong patent moat.

How does Stribild compare with Genvoya and Biktarvy?

Product	Active backbone	Key excipient and commercial implication
Stribild	Elvitegravir/cobicistat/emtricitabine/tenofovir DF	Older TDF-based formulation; strongest generic opportunity but weaker clinical positioning
Genvoya	Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide	TAF-based successor with a newer safety and lifecycle profile
Biktarvy	Bictegravir/emtricitabine/tenofovir alafenamide	Strong commercial competitor with a simplified three-drug regimen and no pharmacokinetic booster

Genvoya was designed as a lifecycle successor to Stribild, replacing tenofovir disoproxil fumarate with tenofovir alafenamide. Biktarvy further simplified treatment by using bictegravir and eliminating cobicistat. These products reduce long-term demand for Stribild and weaken the pricing power of a late entrant.

For excipient suppliers, the broader opportunity is not limited to Stribild. The same capabilities in moisture control, blend uniformity, direct compression, and film coating can transfer to Genvoya, Biktarvy, and other high-value antiretroviral products.

What litigation and settlement issues affect Stribild?

Stribild-related litigation risk has historically centered on patents covering elvitegravir, cobicistat, combination therapy, and related antiretroviral technology. A generic applicant could face:

• Paragraph IV patent litigation after ANDA notice
• A 30-month stay of approval under the Hatch-Waxman framework, subject to statutory conditions
• Settlement restrictions affecting launch timing
• At-risk launch exposure if approval is available before final patent resolution
• Claims involving active-ingredient patents not reflected in the excipient composition

Excipient substitutions normally do not avoid a patent claim directed to the fixed-dose combination itself. Conversely, an excipient-specific claim may be avoidable through a different grade, quantity, or manufacturing process. Freedom-to-operate analysis should therefore map composition, process, solid-state, impurity, and method-of-use claims separately.

What is the FDA regulatory status of Stribild?

Stribild is an FDA-approved prescription antiretroviral product. A generic applicant would generally use the ANDA pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug [1, 4].

The regulatory strategy should include:

1. Reference-product characterization using multiple commercial lots.
2. Comparative dissolution across relevant pH conditions.
3. Excipient compatibility and forced-degradation studies.
4. Stability testing under ICH conditions.
5. Content-uniformity assessment focused on low-dose actives.
6. Evaluation of packaging moisture protection.
7. Appropriate patent certifications under the Hatch-Waxman Act.

The product is not a biologic. Biosimilar risk is therefore irrelevant. Competition would come from chemically synthesized generic products, authorized generics, and alternative branded antiretroviral regimens.

How strong is the Stribild patent estate?

The historical patent estate was commercially meaningful because it combined multiple active pharmaceutical ingredients and a proprietary booster strategy. Its present strength is lower because:

• NCE exclusivity expired years ago.
• The active ingredients have been commercially established.
• The formulation uses conventional excipients.
• The market has shifted toward newer regimens.
• Any remaining patent value depends on claim scope, expiry, pediatric extensions, and litigation outcomes.

The strongest residual barriers are likely to be combination claims, active-ingredient or solid-state claims, and method-of-use claims rather than ordinary excipient selection. A generic sponsor should treat excipient redesign as a risk-reduction tool, not as the primary route around Stribild intellectual property.

Key Takeaways

• Stribild uses a conventional immediate-release film-coated tablet with lactose, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, silicon dioxide, sodium lauryl sulfate, and a standard film coat.
• The best generic strategy is close formulation matching with tight control of blend uniformity, moisture, dissolution, and low-dose active content.
• Lactose-free, co-processed, and direct-compression variants are technically feasible but require comparative performance data.
• Stribild’s FDA NCE exclusivity began in 2012 and generally expired in 2017.
• Stribild is not subject to biosimilar competition. Generic competition proceeds through the ANDA pathway.
• The principal remaining IP risks are likely to involve active ingredients, fixed-dose combinations, solid-state forms, manufacturing processes, and methods of use.
• Commercial demand is constrained by Genvoya, Biktarvy, and other newer HIV regimens.
• The strongest excipient opportunity lies in formulation-enabling services, moisture-control systems, high-uniformity excipients, and transferable platform technologies.

FAQs

Can a generic Stribild tablet use different colors?

Yes. A different color may be possible if it does not create medication-error risk and the labeling, appearance, and stability package are acceptable to regulators. The colorant change must be evaluated for compatibility and product identification.

Does Stribild require a modified-release excipient system?

No. Stribild is an immediate-release tablet. Modified-release excipients would add technical and regulatory complexity without an obvious therapeutic advantage.

Which excipient presents the greatest manufacturing risk?

The highest practical risk comes from the interaction between the disintegrant, lubricant, surfactant, and moisture-sensitive tenofovir disoproxil fumarate. The individual excipients are standard, but their levels and processing sequence affect dissolution and stability.

Could a manufacturer create a chewable Stribild product?

A chewable product would require a new formulation and clinical or bioequivalence assessment. Taste masking, dose uniformity, excipient tolerability, and altered dissolution would be central development issues.

Is Stribild still commercially attractive for contract manufacturers?

It can be attractive where demand remains in price-sensitive markets, government tenders, or regions with limited access to newer regimens. The opportunity is weaker in markets where treatment guidelines and payer formularies favor Biktarvy, Genvoya, or other newer combinations.

References

1. U.S. Food and Drug Administration. (2012). Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: Stribild, elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for industry.